Evidence map›Paper›PMID 21708033›Full record

ArticleArthritis research & therapy2011

Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus.

Eric S Sobel, Todd M Brusko, Ed J Butfiloski, Wei Hou, Shiwu Li, Carla M Cuda, Ariana N Abid, Westley H Reeves, Laurence Morel

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Lupus susceptibility geneScience advances · 2024
    Article
  4. Review
  5. Article
  6. Human CD4Frontiers in immunology · 2022
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Metabolic Factors that Contribute to Lupus Pathogenesis.Critical reviews in immunology · 2016
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eric S SobelDepartment of Medicine, Division of Rheumatology and Clinical Medicine, University of Florida, 1600 Archer Road, Gainesville, FL 32610-0275, USA.
Todd M Brusko
Ed J Butfiloski
Wei Hou
Shiwu Li
Carla M Cuda
Ariana N Abid
Westley H Reeves
Laurence Morel
University of Florida · USNorthwestern University · US

Funding

Characterization of SLE-susceptibility loci on mouse chromosome 1R01AI045050 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Laurence Morel · 2000 to 2026
$11.5M
NIAID NIH HHS R01-AI045050
6 · The paper itself

Abstract

introductionCD25(+) FOXP3(+) CD4(+) regulatory T cells (Tregs) are induced by transforming growth factor β (TGFβ) and further expanded by retinoic acid (RA). We have previously shown that this process was defective in T cells from lupus-prone mice expressing the novel isoform of the Pbx1 gene, Pbx1-d. This study tested the hypothesis that CD4(+) T cells from systemic lupus erythematosus (SLE) patients exhibited similar defects in Treg induction in response to TGFβ and RA, and that PBX1-d expression is associated with this defect.

methodsPeripheral blood mononuclear cells (PBMCs) were collected from 142 SLE patients and 83 healthy controls (HCs). The frequency of total, memory and naïve CD4(+) T cells was measured by flow cytometry on fresh cells. PBX1 isoform expression in purified CD4(+) T cells was determined by reverse transcription polymerase chain reaction (RT-PCR). PBMCs were stimulated for three days with anti-CD3 and anti-CD28 in the presence or absence of TGFβ and RA. The expression of CD25 and FOXP3 on CD4(+) T cells was then determined by flow cytometry. In vitro suppression assays were performed with sorted CD25(+) and CD25(-) FOXP3(+) T cells. CD4(+) T cell subsets or their expansion were compared between patients and HCs with two-tailed Mann-Whitney tests and correlations between the frequencies of two subsets were tested with Spearman tests.

resultsThe percentage of CD25(-) FOXP3(+) CD4(+) (CD25(-) Tregs) T cells was greater in SLE patients than in HCs, but these cells, contrary to their matched CD25(+) counterparts, did not show a suppressive activity. RA-expansion of TGFβ-induced CD25(+) Tregs was significantly lower in SLE patients than in HCs, although SLE Tregs expanded significantly more than HCs in response to either RA or TGFβ alone. Defective responses were also observed for the SLE CD25(-) Tregs and CD25(+) FOXP3(-) activated CD4(+) T cells as compared to controls. PBX1-d expression did not affect Treg induction, but it significantly reduced the expansion of CD25- Tregs and prevented the reduction of the activated CD25(+) FOXP3(-) CD4(+) T cell subset by the combination of TGFβ and RA.

conclusionsWe demonstrated that the induction of Tregs by TGFβ and RA was defective in SLE patients and that PBX1-d expression in CD4(+) T cells is associated with an impaired regulation of FOXP3 and CD25 by TGFβ and RA on these cells. These results suggest an impaired integration of the TGFβ and RA signals in SLE T cells and implicate the PBX1 gene in this process.

Indexed as

AdultAgedAntineoplastic AgentsCD4-Positive T-LymphocytesCell DivisionCells, CulturedFemaleFlow CytometryForkhead Transcription FactorsHumansImmunologic MemoryInterleukin-2 Receptor alpha SubunitInterleukin-7 Receptor alpha SubunitLeukocyte Common AntigensLupus Erythematosus, SystemicMaleAntineoplastic AgentsForkhead Transcription FactorsFOXP3 protein, humanIL2RA protein, humanInterleukin-2 Receptor alpha SubunitInterleukin-7 Receptor alpha SubunitLeukocyte Common AntigensTransforming Growth Factor betaTretinoin

Identifiers

PMID21708033
PMCPMC3218921
OpenAlexW2130909166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.